Acacia Pharma initiates two pivotal Phase 3 studies of APD421 in prevention of PONV Acacia Pharma.

Acacia Pharma's CEO, Dr Julian Gilbert, added: We are delighted to possess initiated these Phase 3 studies so soon after securing our latest funding. The Phase 2 data we generated last year were excellent and we are assured of obtaining similar outcomes in these larger pivotal clinical studies. .. Acacia Pharma initiates two pivotal Phase 3 studies of APD421 in prevention of PONV Acacia Pharma, a pharmaceutical organization specialising in the development of drugs for supportive treatment, announces the initiation of two pivotal Stage 3 research of APD421 in the prevention of post-operative nausea & vomiting . PONV continues to be a significant problem in individuals undergoing major medical procedures clinically, despite the option of a range of anti-emetic medications.Filed a lawsuit in the U.S. District Courtroom for the District of Minnesota today against Andover Health care Inc. Seeking injunctive comfort and damages regarding Andover’s CoFlex 2 Coating Compression System. The match alleges, among other promises, a strong likelihood of misunderstandings, mistake and deception between Andover’s CoFlex 2 item and 3M’s innovative Coban 2 Level Compression System due to Andover’s wholesale appropriation of 3M’s distinctive trade outfit, copyrighted product packaging and copyrighted instructions. The suit alleges false advertising and unfair business practices also. Related StoriesHealthcare technology cultural event of the year opens entriesOJ Bio at Medica 2015 – Stage of Care diagnostics' role in reducing antibiotics prescribingReducing hospital readmissions through Transitional Care: an interview with Rani KhetarpalCompression therapy is considered a standard of look after treating venous hypertension and venous ulcers, which are a serious issue for many Americans, including the elderly and people with vascular disease or poor circulation.